Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination.

Join-Lambert O, Ribadeau-Dumas F, Jullien V, Kitzis MD, Jais JP, Coignard-Biehler H, Guet-Revillet H, Consigny PH, Delage M, Nassif X, Lortholary O, Nassif A.

Eur J Dermatol. 2014 Jan-Feb;24(1):94-5. doi: 10.1684/ejd.2013.2213. No abstract available.

PMID:
24445967
2.

Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.

Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, Fantin B.

Int J Antimicrob Agents. 2014 Apr;43(4):366-9. doi: 10.1016/j.ijantimicag.2013.12.001. Epub 2013 Dec 11.

PMID:
24388117
3.

Diagnosis and treatment strategies for community-acquired Streptococcus salivarius meningitis.

Vignier N, Couzigou C, Nguyen Van JC, Gerber S, Gaillard S, Bruel C, Misset B, Kitzis MD, Le Monnier A.

Med Mal Infect. 2014 Jan;44(1):42-4. doi: 10.1016/j.medmal.2013.10.005. Epub 2013 Nov 22. No abstract available.

PMID:
24274977
4.

Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study.

Dubée V, Zeller V, Lhotellier L, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N.

Clin Microbiol Infect. 2013 Feb;19(2):E98-105. doi: 10.1111/1469-0691.12071. Epub 2012 Dec 10.

5.

Ten-year decrease of acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at a single institution: the result of a multifaceted program combining cross-transmission prevention and antimicrobial stewardship.

Chalfine A, Kitzis MD, Bezie Y, Benali A, Perniceni L, Nguyen JC, Dumay MF, Gonot J, Rejasse G, Goldstein F, Carlet J, Misset B.

Antimicrob Resist Infect Control. 2012 May 18;1(1):18. doi: 10.1186/2047-2994-1-18.

6.

Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats.

Le Saché N, Baud O, Pansiot J, Pham H, Biran V, Brunel-Meunier N, Bidet P, Kitzis MD, Gressens P, Bingen E, Charriaut-Marlangue C, Bonacorsi S.

Antimicrob Agents Chemother. 2011 Jul;55(7):3567-9. doi: 10.1128/AAC.01813-10. Epub 2011 Apr 18.

7.

Ciprofloxacin prevents myelination delay in neonatal rats subjected to E. coli sepsis.

Loron G, Olivier P, See H, Le Saché N, Angulo L, Biran V, Brunelle N, Besson-Lescure B, Kitzis MD, Pansiot J, Bingen E, Gressens P, Bonacorsi S, Baud O.

Ann Neurol. 2011 Feb;69(2):341-51. doi: 10.1002/ana.22190. Epub 2010 Oct 27.

PMID:
21387379
8.

In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy CJ.

Int J Antimicrob Agents. 2011 Mar;37(3):235-9. doi: 10.1016/j.ijantimicag.2010.11.035. Epub 2011 Feb 4.

9.

In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Lascols C, Legrand P, Mérens A, Leclercq R, Armand-Lefevre L, Drugeon HB, Kitzis MD, Muller-Serieys C, Reverdy ME, Roussel-Delvallez M, Moubareck C, Lemire A, Miara A, Gjoklaj M, Soussy CJ.

Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):475-82. doi: 10.1007/s10096-010-1117-6. Epub 2010 Nov 19. Review.

10.

Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.

Zeller V, Dzeing-Ella A, Kitzis MD, Ziza JM, Mamoudy P, Desplaces N.

Antimicrob Agents Chemother. 2010 Jan;54(1):88-92. doi: 10.1128/AAC.01081-09. Epub 2009 Oct 19.

11.

Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Skurnik D, Lasocki S, Bremont S, Muller-Serieys C, Kitzis MD, Courvalin P, Andremont A, Montravers P.

J Med Microbiol. 2010 Jan;59(Pt 1):115-9. doi: 10.1099/jmm.0.012468-0.

PMID:
19745032
12.

Drug-to-drug interaction between dapsone and minocycline: an unusual cause of relapse of toxoplasmic encephalitis in an HIV-infected patient.

Gallien S, Bigé N, Kitzis MD, Longuet P, Gervais A, Leport C.

Scand J Infect Dis. 2009;41(9):700-2. doi: 10.1080/00365540903140691.

PMID:
19634069
13.

Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Zeller V, Durand F, Kitzis MD, Lhotellier L, Ziza JM, Mamoudy P, Desplaces N.

Antimicrob Agents Chemother. 2009 Mar;53(3):883-7. doi: 10.1128/AAC.00389-08. Epub 2008 Dec 15.

14.

[Pleural diffusion of amoxicillin 1 and vancomycin in patients treated for post-surgical empyema].

Stern JB, Péan Y, Girard P, Kitzis MD, Caliandro R, Grima R, Gossot D, Debrosse D, Schussler O, Magdeleinat P.

Rev Mal Respir. 2007 Sep;24(7):853-8. French.

PMID:
17925667
15.

Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.

Goldstein F, Perutka J, Cuirolo A, Plata K, Faccone D, Morris J, Sournia A, Kitzis MD, Ly A, Archer G, Rosato AE.

Antimicrob Agents Chemother. 2007 Jul;51(7):2514-22. Epub 2007 Apr 30.

16.

Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin.

Goldstein FW, Ly A, Kitzis MD.

J Antimicrob Chemother. 2007 May;59(5):1039-40. Epub 2007 Apr 16. No abstract available.

PMID:
17437963
17.

Hip arthroplasty infection with heterogeneous vancomycin-resistant Staphylococcus aureus.

Zeller V, Kitzis MD, Graff W, Mamoudy P, Desplaces N.

Scand J Infect Dis. 2006;38(10):934-8.

PMID:
17008244
18.

Highly sensitive and efficient computer-assisted system for routine surveillance for surgical site infection.

Chalfine A, Cauet D, Lin WC, Gonot J, Calvo-Verjat N, Dazza FE, Billuart O, Kitzis MD, Blériot JP, Pibarot ML, Carlet J.

Infect Control Hosp Epidemiol. 2006 Aug;27(8):794-801. Epub 2006 Jul 20.

PMID:
16874638
19.

Telithromycin-resistant Streptococcus pneumoniae.

Goldstein F, Vidal B, Kitzis MD.

Emerg Infect Dis. 2005 Sep;11(9):1489-90. No abstract available.

20.

[Detection of nasal colonization methicillin-resistant Staphylococcus aureus: a prospective study comparing real-time genic amplification assay vs selective chromogenic media].

Nguyen Van JC, Kitzis MD, Ly A, Chalfine A, Carlet J, Ben Ali A, Goldstein F.

Pathol Biol (Paris). 2006 May;54(5):285-92. Epub 2006 Mar 10. French.

PMID:
16530352
21.

Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.

Kitzis MD, Goldstein FW.

Clin Microbiol Infect. 2006 Jan;12(1):92-5.

22.

False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.

Goldstein FW, Atoui R, Ben Ali A, Nguyen JC, Ly A, Kitzis MD.

Clin Microbiol Infect. 2004 Apr;10(4):342-5.

23.

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.

Kitzis MD, Ly A, Goldstein FW.

Antimicrob Agents Chemother. 2004 Jan;48(1):366-7. No abstract available.

24.

Vancomycin-resistant Staphylococcus aureus: no apocalypse now.

Goldstein FW, Kitzis MD.

Clin Microbiol Infect. 2003 Aug;9(8):761-5.

26.

False susceptibility of Klebsiella oxytoca to some extended-spectrum cephalosporins.

Granier SA, Nicolas-Chanoine MH, Nguyen Van JC, Leflon-Guibout V, Kitzis MD, Goldstein FW.

J Antimicrob Chemother. 2002 Aug;50(2):303-4. No abstract available.

PMID:
12161419
27.

First description of a TEM-30 (IRT-2)-producing Klebsiella oxytoca isolate.

Granier SA, Nguyen Van JC, Kitzis MD, Goldstein FW, Leflon-Guibout V, Nicolas-Chanoine MH.

Antimicrob Agents Chemother. 2002 Apr;46(4):1158-9. No abstract available.

28.

New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Janoir C, Varon E, Kitzis MD, Gutmann L.

Antimicrob Agents Chemother. 2001 Mar;45(3):952-5.

29.

In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.

Soussy CJ, Cluzel M, Ploy MC, Kitzis MD, Morel C, Bryskier A, Courvalin P.

J Antimicrob Chemother. 1999 Jun;43 Suppl C:43-50.

PMID:
10404337
30.

In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.

Kitzis MD, Goldstein FW, Miegi M, Acar JF.

J Antimicrob Chemother. 1999 Jun;43 Suppl C:21-6.

PMID:
10404333
32.

ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.

Varon E, Janoir C, Kitzis MD, Gutmann L.

Antimicrob Agents Chemother. 1999 Feb;43(2):302-6.

33.

[Changes in ceftazidime concentration in the CSF following overdose in acute kidney failure].

Garrec F, Bensousan T, Kitzis MD, Leclercq B.

Therapie. 1998 Sep-Oct;53(5):516-7. French. No abstract available.

PMID:
9921053
34.

[Antibacterial activity of ofloxacin in urine for 4 days after a single oral dose of 400 mg].

Guibert J, Kitzis MD, Acar JF.

Pathol Biol (Paris). 1998 Oct;46(8):656-60. French.

PMID:
9871938
35.

In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae.

Sifaoui F, Varon E, Kitzis MD, Gutmann L.

Antimicrob Agents Chemother. 1998 Jan;42(1):173-5.

36.

Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ.

Antimicrob Agents Chemother. 1997 Sep;41(9):1973-8.

37.

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L.

Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4.

38.

[In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].

Soussy CJ, Cluzel M, Derlot E, Exmelin L, Kitzis MD, Dabernat H, Le Noc P, Muller-Serieys C, Reverdy ME, Scheftel JM, Thabaut A.

Pathol Biol (Paris). 1996 Apr;44(4):241-8. French.

PMID:
8763585
40.

[Comparative study of the performance and ergonomics of nebulizers in cystic fibrosis].

Faurisson F, Dessanges JF, Grimfeld A, Beaulieu R, Kitzis MD, Peytavin G, Lefevre JP, Farinotti R, Sautegeau A.

Rev Mal Respir. 1996;13(2):155-62. French.

PMID:
8711234
41.

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications].

Chaïbi EB, Mugnier P, Kitzis MD, Goldstein FW, Acar JF.

Res Microbiol. 1995 Nov-Dec;146(9):761-71. Review. French.

PMID:
8584798
42.

SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci.

Kitzis MD, Goldstein FW, Ishida N, Acar JF.

J Antimicrob Chemother. 1995 Jul;36(1):209-13.

PMID:
8537267
44.

Nebulizer performance: AFLM study. Association Française de Lutte contre la Mucoviscidose.

Faurisson F, Dessanges JF, Grimfeld A, Beaulieu R, Kitzis MD, Peytavin G, Lefebvre JP, Farinotti R, Sautegeau A.

Respiration. 1995;62 Suppl 1:13-8.

PMID:
7792434
45.

Screening for extended-spectrum cephalosporin resistance in Streptococcus pneumoniae.

Goldstein FW, Kitzis MD, Acar JF.

J Antimicrob Chemother. 1994 Dec;34(6):1076-7. No abstract available.

PMID:
7730226
47.

[Antibacterial activity of ciprofloxacin in the urine during four days after a single 500 mg and 750 mg oral dose].

Guibert J, Kitzis MD, Acar JF.

Pathol Biol (Paris). 1994 Jun;42(6):587-92. French.

PMID:
7854859
48.
49.

[In vitro antibacterial activity of a new fluoroquinolone, fleroxacin, against hospital bacteria and regression curve].

Soussy CJ, Cluzel M, Derlot E, Kitzis MD, Meyran M.

Pathol Biol (Paris). 1994 May;42(5):385-92. French.

PMID:
7824301

Supplemental Content

Loading ...
Support Center